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Abstract  
Objective:  This study aimed to determine 5-year progression-free and overall survival in 
patients with uterine carcinosarcoma, to determine clinical and surgical-pathologic features, to 
recognize patterns of recurrence and to identify prognostic factors influencing progression-free 
survival (PFS) and overall survival (OS). 
Materials and Methods:  A total of 61 patients with uterine carcinosarcoma who were 
diagnosed between January 2005 and December 2014 were included.  Demographic, 
clinicopathological, treatment and outcome information were obtained.  Kaplan-Meier survival 
analysis and Cox proportional hazards models were used to determine the effects of variables 
on PFS and OS. 
Results:  Eighteen patients (29%) presented as FIGO stage I disease, 5 patients (8%) as 
stage II, 16 patients (26%) as stage III and 22 patients (36%) as stage IV disease, of which 50 
patients (82%) had surgery.  Seventeen patients presented with recurrence of which 5 (29.4%) 
were local and 12 (70.6%) were outside the pelvis.  Five-year PFS and 5-year OS were 17.3% 
(CI 8.9%-27.9%) and 19.7% (CI 10.6%-30.8%), respectively.  In the univariate analysis, tumour 
diameter ≥ 100mm (HR 4.57, p-value 0.005) was associated with 5-year PFS and in univariate 
analysis of OS, a positive family history (HR 0.42, p-value 0.047), receiving a full staging 
operation (HR 0.37, p-value 0.008) and receiving any other modality of treatment, with or 
without surgery, (HR 0.48, p-value 0.012) was associated with better survival.  An abnormal 
pap smear (HR 2.4, p-value 0.041), late-stage disease (HR 3.48, p-value < 0.001), presence 
of residual tumour (HR 3.66, p-value < 0.001), myometrial invasion more than 50% (HR 2.29, 
p-value 0.019), cervical involvement (HR 3.38, p-value 0.001) and adnexal involvement (HR 
3.21, p-value 0.002) were associated with a higher risk of death.  In the multivariate analysis, 
full staging operation was associated with a risk of progression of disease (HR 3.49, p-value 
0.025).  Advanced stage (HR 4.2, p-value < 0.001) was associated with a higher risk of death.  
Any other modality of treatment (HR 0.28, p-value < 0.001) and full staging laparotomy (HR 
0.27, p-value 0.001) was a protective factor for death. 
Conclusions:  Carcinosarcoma is an aggressive cancer with poorer survival than previously 
described.  Biological or genetic factors may play a role in our study population.  Most 
recurrences occur outside of the pelvis.  Full staging surgery (including pelvic 
lymphadenectomy) and additional use of other modalities (either for radical or palliative intent) 
improve survival. 
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Glossary 
Progression-free survival (PFS):  Date of diagnosis to the date of first recurrence or 
progression of disease, or in absence of recurrence, to the date of the last follow-up or death. 
Overall survival (OS):  Date of diagnosis to the date of all-cause death or last follow-up. 
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1 Introduction 
Uterine carcinosarcomas are rare, aggressive tumours.  No clinicopathological, prognostic or 
outcome data about this tumour type is known on the African continent.  The predictors of 
progression-free survival and overall survival have not been determined clearly yet.  Identifying 
prognostic factors is important to better define patients who would benefit from relevant 
treatment strategies and to plan further clinical trials.  In this thesis, an extensive literature 
review will be conducted.  A retrospective review of patients treated with uterine 
carcinosarcoma between 2005 – 2014 at the study institution will be done and the following 
primary and secondary outcomes will be evaluated: 
1.1 Primary outcomes: 
• Determination of 5-year overall survival (OS) 
• Determination of 5-year progression-free survival (PFS) 
1.2 Secondary outcomes: 
• Define the clinical characteristics of the patient population  
• Describe the surgical-pathological characteristics of the study cohort 
• Describe other employed modalities (apart from surgery) in the treatment of patients 
• Recognize common sites and patterns of recurrence 
• Identify prognostic factors that affect disease-free survival and overall survival in the 
study population 
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2 Literature review 
2.1 Introduction 
Uterine carcinosarcomas are rare, aggressive tumours.  Traditionally, they have been 
considered as a subtype of uterine sarcoma and oncological treatments have been directed 
against the sarcomatous histological type.  They are now regarded as uterine carcinomas.  
They present with advanced disease in the majority of cases and multiple studies have 
confirmed their poorer overall survival when compared to high grade endometrioid endometrial 
carcinomas and other uterine carcinomas high-risk variants1–6. 
2.2 Epidemiology 
Their 5-year overall outcome is poor, with survival ranging from 33 to 39%7,8.  Even in apparent 
early-stage (disease limited to the uterus), the rate of relapse is more than 50%9,10.  The 
worldwide annual incidence according to an old population-based study is between 0.5 and 
3.3 cases per 100,000 women and it compromises only 2-3% of uterine cancers11.  In US-
based studies, uterine carcinosarcoma occurs more frequent after age 69 and black race is a 
significant risk factor for the development of uterine sarcoma and poor survival11–14.  In a large 
SEER (Surveillance, Epidemiology, and End Results) analysis, it was confirmed that the total 
age-adjusted incidence for blacks was two times that of whites and more than twofold that of 
women of other races15. 
2.3 Classification 
Carcinosarcoma (synonyms: metaplastic carcinoma, malignant mixed müllerian - or 
mesodermal tumour) is classified as a tumour composed of a combination of malignant 
epithelial and mesenchymal components in the World Health Organization classification of 
gynaecological neoplasms16.  Although these tumours are still classified as “mixed” by 
convention, there is substantial evidence that they are monoclonal in origin and should be 
considered a subset of endometrial carcinoma.  For this reason, they are currently classified 
in the 2009 FIGO (International Federation of Gynecology and Obstetrics) staging system 
together with endometrial carcinoma17.   
2.4 Pathology 
The carcinomatous component usually consists of a serous (most common) or endometrioid 
component.  Rarely, it may consist of a mucinous, clear cell or squamous cell carcinoma.  The 
sarcomatous homologous component can resemble malignant fibrous histiocytoma, 
fibrosarcoma, leiomyosarcoma, high grade endometrial stromal sarcoma, undifferentiated 
sarcoma or a mixture thereof.  If there is a heterologous element present, it most frequently 
contains cartilage or malignant skeletal muscle resembling either embryonal 
rhabdomyosarcoma or pleomorphic rhabdomyosarcoma.  Osteosarcoma or liposarcoma can 
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also be present.  Neuronal, glial, yolk sac, melanocytic, trophoblastic and angiomatoid 
differentiation may be encountered18. 
Molecular, histopathological and clinical data have confirmed that most uterine 
carcinosarcomas are derived from a single stem cell and are in fact monoclonal in origin.  The 
sarcomatous element is derived as a result of dedifferentiation of the carcinomatous 
component, and the carcinomatous component is the dominant part of this tumour.  Clinical 
data in support of the above hypotheses is the fact that uterine carcinosarcoma shares similar 
risk factors to endometrial carcinoma.  Both are associated with nulliparity, exogenous 
estrogen use, obesity and oral contraceptives are known to offer a protective effect against 
their development.  Also, both may occur in association with previous radiation exposure or 
tamoxifen therapy19–24.  The location and pattern of sites of metastatic disease in uterine 
carcinosarcoma resemble that of aggressive endometrial cancer rather than uterine sarcomas 
(lymphatic rather than hematogenous)25,26.  Similarly, most deaths in patients with uterine 
carcinosarcoma are due to recurrent abdominal or local pelvic disease rather than distant 
metastatic disease9.  Histopathological studies have shown that metastatic tumour deposits 
and tumour emboli in lymphovascular channels almost always consist of the carcinomatous 
elements25,27.  Pure/Coexistent sarcomatous elements are uncommon in metastatic foci.  
Immunohistochemical studies have shown the expression of epithelial markers in the 
sarcomatous element28 and other studies have confirmed concordance of p53, p16 and PAX8 
staining between the sarcomatous and carcinomatous components in single tumours29–31.  The 
dominant role of the carcinomatous component in carcinosarcoma is emphasized by 
immunohistochemical studies showing more expression of proteins involved in angiogenesis, 
higher mitotic and proliferation index, lower apoptotic index in the carcinomatous component 
compared to the sarcomatous component32–34.  Lastly, clonality studies confirmed the 
monoclonal origin of the epithelial and stromal components in carcinosarcomas35.  The 
presence of tumours with a distinct biclonal origin has been reported but the clinical 
implications and prognosis of this cohort are not yet well-defined36. 
2.5 Prognostic factors 
Several pathological factors have been associated with recurrence and survival.  These 
include age, disease stage, positive cytology, myometrial invasion depth, LVSI 
(Lymphovascular Space Invasion), adnexal and serosal involvement, abnormal Ca-125 levels, 
residual tumour greater than 1cm, performance status 2 to 4, lymph node metastases and 
number of lymph nodes collected 37–41.  The prognostic significance of the existence of 
heterologous versus homologous sarcomatous components is controversial.  Several studies 
have found that the presence of heterologous elements carries no prognostic 
significance39,42,43, but others have found it to be a powerful negative prognostic factor3,9,44. 
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2.6 Management of uterine carcinosarcoma 
2.6.1 Surgical management 
Due to the rarity of uterine carcinosarcoma, prospective trials to establish optimal treatment 
regimens are limited and most evidence-based treatment algorithms are based on mostly 
retrospective studies.  The National Comprehensive Cancer Network (NCCN) recommends a 
total abdominal hysterectomy, bilateral salpingo-oophorectomy and pelvic nodal dissection.  It 
also states that para-aortic nodal evaluation may be utilized for staging and omental biopsy 
should also be performed.  Maximal tumour debulking of gross disease should also be 
considered45.   
Studies supporting aggressive surgical cytoreduction in advanced-stage uterine 
carcinosarcoma are lacking.  The principle and benefit of cytoreductive surgery are largely 
unknown in this population.  Only two retrospective studies to date evaluated the role of 
cytoreductive surgery in this population group.  One retrospective study evaluated the role of 
complete gross resection in stage III-IV uterine carcinosarcoma and did demonstrate that 
resection to no visible disease was associated with improved overall survival (52.3 versus 8.6 
months)46.  A multi-institutional retrospective study from the Japanese gynecologic oncology 
group also concluded that optimal cytoreductive surgery (to residual tumour less than 1cm) 
and pelvic lymph node dissection are associated with improved OS in advanced uterine 
carcinosarcoma patients (median OS 37.9 versus 18 months)47.  A literature review that was 
published by Vorgias et al.7 discussing and evaluating the role of lymphadenectomy in uterine 
carcinosarcomas, concluded that it is mandatory for staging purposes and that most 
retrospective studies confirm a significant survival advantage.  The potential mechanisms for 
the improvement in survival are postulated to be from the removal of micro-metastatic foci, 
reduction of recurrence risk (removal of ‘‘target tissue’’) and mechanical circumvallate.  
Likewise, studies are also in support of performing omentectomy48,49. 
2.6.2 Adjuvant therapy 
The role of adjuvant treatment in carcinosarcoma is controversial and still debated in the 
literature.  Approximately 50% of patients with surgical stage I carcinosarcoma who do not 
receive adjuvant therapy will experience a recurrence and most of them will recur distally50. 
There is no clear agreement about the best possible adjuvant treatment (chemotherapy, 
radiation or a combination thereof) and no alternative treatment approaches exist for various 
disease stages.  Randomized trials are limited due to the rarity of this tumour type and most 
institutions have their own individualized adjuvant treatment approach. 
2.6.2.1 Chemotherapy 
Recommendations for adjuvant chemotherapy in early-stage disease are not based on strong 
evidence.  Only limited retrospective data are available to guide treatment.  One of the largest 
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multi-institutional reviews to date found that adjuvant chemotherapy was significantly 
associated with improved PFS and OS was improved only in the absence of LVSI51.  In patients 
with advanced-stage disease, adjuvant chemotherapy can be considered, but the optimal 
chemotherapeutic regime is still being investigated.   
A Gynecologic Oncology Group randomized phase III trial (GOG 150) of whole abdominal 
irradiation (WAI) versus cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage 
I-IV uterine carcinosarcoma did not find a statistically significant advantage in recurrence rate 
or survival for adjuvant CIM over WAI.  However, the observed differences favoured the use 
of combination chemotherapy52.  Another GOG randomized phase III trial in advanced uterine 
carcinosarcoma demonstrated a superior OS for combination chemotherapy (ifosfamide with 
paclitaxel) compared with single-agent treatment (ifosfamide alone)53.  GOG 261, the latest 
randomized phase III trial comparing the combination of carboplatin and paclitaxel versus the 
combination of ifosfamide and paclitaxel for UCS, is ongoing (NCT00954174). 
2.6.2.2 Neoadjuvant chemotherapy 
The role of neoadjuvant chemotherapy in UCS is not well described.  Only one nested case-
control study within a multicenter retrospective cohort examined the role of neoadjuvant 
chemotherapy in patients with stage IV UCS54.  Patients who received neoadjuvant 
chemotherapy followed by hysterectomy-based surgery for stage IV UCS were compared to 
women who had primary hysterectomy-based surgery without neoadjuvant chemotherapy.  
The analysis showed no statistically significant difference in survival outcomes between these 
two groups of women with advanced uterine carcinosarcoma.  
2.6.2.3 Radiotherapy 
The role and benefit of radiotherapy in die adjuvant setting in patients treated surgically for 
UCS are controversial.  Numerous small retrospective series have studied the benefit of 
adjuvant radiotherapy in UCS.  Most have shown a consistent decrease in pelvic failures, but 
no significant effect on overall survival55–60.  Some studies have claimed an OS benefit with 
adjuvant pelvic irradiation for patients with stage I-II disease61,62 and some only for stage I 
disease63.  Others have shown no benefit in terms of local control or overall survival rates64.  
In a large National Cancer Database review65, EBRT (External Beam Radiation Therapy) and 
brachytherapy combination were associated with an overall survival advantage in the 
adjunctive setting of uterine carcinosarcoma, but not among those receiving EBRT or 
brachytherapy alone.  A large SEER analysis including 1 891 women with early-stage UCS 
demonstrated that overall survival with pelvic radiotherapy was only improved in patients who 
did not receive lymphadenectomy as part of the initial surgery and only had a small effect on 
survival in women with negative nodes66.  This is in contrast to another large SEER analysis 
which demonstrated that adjuvant radiation therapy had no improvement in overall survival 
regardless of lymphadenectomy in patients with stage I-III disease67.  A randomized phase III 
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trial conducted by the European Organization for Research and Treatment of Cancer, 
evaluated the role of adjuvant pelvic radiotherapy for early-stage uterine sarcomas (including 
91 patients with UCS)68.  Their results were consistent with most of the retrospective studies – 
confirming a trend towards better local control (but also higher distant metastatic rate) and no 
significant impact on either PFS or OS.  In the Gynecologic Oncology Group 150 trial52 
(mentioned previously) comparing whole abdominal irradiation and cisplatin-ifosfamide with 
mesna as adjuvant therapy, patients in the irradiation group were likely to experience 
abdominal recurrence and serious late adverse events.  Patients receiving chemotherapy only 
had a higher probability to experience a vaginal recurrence. 
2.6.2.4 Combination therapy 
The findings of GOG 15052 estimated high crude probabilities of recurrence in both radiation 
and chemotherapy arms (52% relapse rate at 5 years in the chemotherapy arm and 58% in 
the radiation arm).  Also, the patterns of failure/recurrence between the WAI and CIM group 
(increased vaginal recurrence rate in the chemotherapy cohort versus the radiotherapy cohort; 
notable reduction in abdominal failures in the chemotherapy group as compared to the WAI 
arm) led to the consideration of a combination of radiation and chemotherapy following 
surgery.  The optimal schedule and sequence remain controversial, but several recent 
retrospective and prospective non-randomized trials suggest a longer survival.  They are briefly 
discussed: 
• A phase 2 prospective trial of ‘sandwich’ multimodality therapy in UCS reported it as 
an efficacious regimen for surgically staged UCS patients, but that the efficacy of this 
‘sandwich’ regimen comes with a moderate, but tolerable toxicity profile69.   
• A retrospective, multi-institutional review that aimed to characterize the impact of 
adjuvant therapy on survival in women with stage I-II UCS after primary surgery, 
demonstrated a significantly lower risk of death in women treated with combined 
chemotherapy and radiation compared with women undergoing observation, adjuvant 
radiation only or adjuvant chemotherapy alone.  Freedom from vaginal recurrence 
was also improved with adjuvant chemoradiation70. 
• In a pilot study of 38 patients with clinical stage I or II UCS who underwent surgical 
staging and adjuvant radiation and chemotherapy, survival rates of 74% were 
obtained71.  
• A retrospective review of the Memorial Sloan-Kettering Cancer Centre medical 
records of completely resected stage I-IV UCS with rhabdomyosarcoma 
differentiation suggested that chemotherapy alone or in combination with 
radiotherapy is associated with longer PFS and OS compared to RT alone72. 
• In a retrospective study between different postoperative treatment modalities for 
uterine carcinosarcoma conducted by Menczera et al., chemotherapy, whole pelvic 
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irradiation (WPI) and sequential treatment (i.e., chemotherapy followed by WPI) were 
compared.  It was found that the highest median survival and 5-year survival rate was 
observed in the sequential treatment group73. 
• In a recent retrospective review by Gungorduk et al.74, sequential treatment after 
surgery decreased mortality significantly in both early and advanced-stage disease.  
In early-stage patients (I-II) who received adjuvant chemotherapy with radiation 
therapy, the median DFS and OS were 44 months and 55 months, respectively, 
compared to 34.5 months and 36 months, respectively, in patients who received 
adjuvant radiotherapy or chemotherapy alone.  In advanced-stage patients (III-IV), 
the median DFS and OS of patients receiving adjuvant radiotherapy with 
chemotherapy were 25 months and 38 months, respectively, compared to 23.5 
months and 24.5 months, respectively, in patients receiving adjuvant radiotherapy or 
chemotherapy alone. 
• Odei et al.75 conducted one of the largest retrospective analyses evaluating the 
patterns-of-care and overall survival benefit of adjuvant chemoradiation compared 
with adjuvant chemotherapy among UCS patients.  The findings concluded that, 
when compared with adjuvant chemotherapy alone, the use of adjuvant 
chemoradiation in UCS patients was associated with a significant OS benefit.  
However, multiple demographic and clinical factors significantly influenced the choice 
of adjuvant therapy. 
• A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma (n=303), 
evaluated the use of adjuvant therapy after primary surgery for stage I-III UCS.  
Observation was associated with a fourfold increased risk of death compared to 
chemotherapy.  Multimodality therapy for women with stage I-II disease was 
associated with improved PFS compared to chemotherapy alone76. 
• In the USA, the National Cancer Database hospital registry was used to analyse 
patterns of adjuvant chemotherapy and radiotherapy and to assess the impact on 
survival of each of these treatment regimens in 4 906 patients with UCS confined to 
the pelvis who underwent primary surgery77.  The 5-year OS for patients receiving no 
adjuvant therapy, adjuvant RT alone, adjuvant CT alone, and combined CT and RT 
were 44.9%, 47.1%, 47.5%, and 62.9%, respectively.  The study group concluded 
that combination therapy with chemotherapy and radiotherapy was associated with 
significantly improved 5-year OS compared with no further therapy, radiotherapy 
alone, or chemotherapy alone.   
• In a matched cohort analysis in stage 1 UCS (5 614 women identified from the 
National Cancer Database) to determine if lymphadenectomy, chemotherapy and 
radiotherapy were associated with survival, it was concluded that removal of at least 
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15–20 nodes were associated with increased survival.  Also, vaginal brachytherapy 
with multiagent chemotherapy was associated with increased survival78. 
• In another large National Cancer Database analysis (which included 10 609 patients 
with stage I-IV disease), the objective was to evaluate rates of chemotherapy and 
radiotherapy delivery in the treatment of UCS and to compare clinical outcomes of 
treated and untreated patients.  The lowest hazard ratio for deaths observed was in 
patients that received chemoradiation79. 
• In a study aimed to evaluate the impact of radiation therapy in 155 women with stage 
I-III UCS80, EBRT was associated with higher 5-year pelvic disease control and 
overall survival.  Also, treatment with concurrent chemoradiation therapy was 
independently associated with a higher disease-specific survival rate on multivariate 
analysis (compared with any other or no treatment).  
2.6.2.5 Targeted therapy 
Despite advances in the treatment of UCS, the prognosis remains poor.  Recently, 
immunotherapy targeting known dysfunction molecular pathways have been developed.  In a 
recent systematic review81, the differential expression and accessibility of epithelial cell 
adhesion molecule-1 on metastatic/chemotherapy-resistant UCS cells in comparison to normal 
tissues and Human Epidermal Growth Factor Receptor 2 (HER2) was identified as new 
potential possibilities in the field of target therapy.  The impact of these new therapies on 
survival rates are currently unknown but is being studied. 
The role of hormonal therapy is unclear and has not been studied in UCS.  One case report 
described by Wang et al.82, reported a case of a 69-year old woman with recurrent metastatic 
UCS that responded well to letrozole therapy. The tumour shrunk to less than 25% of its 
original volume. 
2.7 Conclusion 
Most strategies currently used in the treatment of uterine carcinosarcoma are derived from 
retrospective data.  Few prospective trials are available to inform optimal treatment.  From the 
available data, it seems that women with early-stage UCS will benefit from chemotherapy for 
systemic control and radiotherapy for local control.  Women with advanced disease should 
benefit from aggressive cytoreduction followed by combination chemotherapy and radiation for 
local control.  In unresectable disease, neoadjuvant chemotherapy followed by surgery is a 
feasible option.  Quality of life studies is needed to justify the increased toxicity with multimodal 
adjuvant therapy.   
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3 Material and Methods 
Ethical approval was obtained from the Stellenbosch University Health and Research Ethics 
Committee (HREC).  A waiver of consent was also obtained.   
The database of the Unit for Gynecological Oncology at Tygerberg Hospital was reviewed to 
identify patients with pathologically confirmed uterine carcinosarcoma treated between 
January 1st, 2005 and December 31st, 2014.  61 Patients were identified.  Demographic, 
medical, surgical, pathological, follow-up and survival data were collected from all patients.  
Patients were staged according to the 2009 International Federation of Gynecology and 
Obstetrics (FIGO) staging system for endometrial carcinoma.  Staging groups were classified 
as early FIGO stage (I-II) and advanced FIGO stage (III-IV).  In our unit, we regard a full staging 
laparotomy for uterine carcinosarcoma as a total abdominal hysterectomy (TAH) with bilateral 
salpingo-oophorectomy (BSO), infracolic omentectomy and bilateral pelvic lymphadenectomy 
with washings and peritoneal biopsies.  Complete debulking was defined as a procedure where 
no residual macroscopic tumour was left behind during surgery.  
Adjuvant therapy or palliation management was individualized after discussion at a 
multidisciplinary tumour board meeting and was based on the age of the patient, stage of 
disease, performance status and medical co-morbidities.  Patients returned for follow-up 
evaluation (review of symptoms and full clinical examination) after completing treatment every 
three months for the first two years, every six months for the next three years, and annually 
thereafter.  Imaging was only performed if recurrence was suspected.  Survival data was 
censored in August 2018.   
  
Stellenbosch University  https://scholar.sun.ac.za
10 
4 Statistical analysis 
Progression-free survival (PFS) was defined as the date of diagnosis to the date of first 
recurrence or progression of disease, or in absence of recurrence, to the date of the last follow-
up or death.  Overall survival (OS) was calculated from the date of diagnosis to the date of 
death or last follow-up.  For the time to progression, the competing risk of death had to be 
considered since this state prevented a participant to experience the progression event.  A 
competing risks survival analysis of progression was done with death as the competing risk.  
Univariate and multiple regression models were considered for this outcome.  The small 
sample size and number of events was a limiting factor on the complexity of the multiple 
regression model.  Overall survival was modelled using a Cox proportional hazards model.  
Univariate and multiple regression models were considered.  Hazard ratios and 95% 
confidence intervals were estimated and reported.  Kaplan-Meier plots were done to depict the 
survival or incidence curves.  As descriptive statistics, two-way tables of the events and the 
risk factors were tabulated.   
A 5% significance level was used in this study.  The Stata15 software package was used for 
statistical analysis. 
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5 Results 
5.1 Clinical characteristics of the study cohort 
We identified 61 patients with uterine carcinosarcoma during the study period.  Clinical 
characteristics of the patients are shown in Table 5-1.  The mean age at diagnosis was 66 
years and most patients were postmenopausal (97%).  Most patients presented with abnormal 
uterine bleeding (90%), pain (26%), loss of weight (21%) and abnormal discharge (15%).  
Other less common presentations included loss of appetite, fatigue, shortness of breath, 
nausea and vomiting, constipation and dysuria.  Hypertension (52 patients) and diabetes (20 
patients) were the most common comorbid diseases.  Pap smear results were available for 44 
patients.  Twenty-nine patients had an abnormal pap smear.  The detection rate of a pap smear 
to detect uterine malignancy in our UCS population was 65.91%.  Only 2 patients were on 
tamoxifen for previously treated breast cancer and no patients had a history of previous pelvic 
radiotherapy (only 1 patient had a history of breast radiation as part of her treatment for breast 
cancer).  Eighteen patients presented as FIGO stage I disease, 5 patients as FIGO stage II, 
16 patients as FIGO stage III and 22 patients presented as FIGO stage IV disease. 
Five-year overall survival was 19.7% (95%CI 10.6%-30.8%).  This is shown in Figure 5-1.  
Five-year progression-free survival (taking both progression and death as event) was 17.3% 
(95%CI 8.9%-27.9%).  In fact, this progression-free survival is the same as the two-year 
progression-free survival estimate since no event of progression was observed after two years.  
This is shown in Figure 5-2.  A 2-year progression-free survival estimate is more realistic as 
only 8 patients in our cohort were still alive after 5 years of follow-up.   
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Table 5-1: Clinical characteristics of the study population 
Characteristic Value (n=61) 
Mean age at diagnosis, years (range) 66.77 (35.08-81.6) 
Gravidity (median) 4  
Parity (median) 4  
BMI (kg/m2)  
Mean (range) 32.86 (20.60-56.24) 
Menopausal status No (%) 
Premenopausal 2 (3.28) 
Postmenopausal 59 (96.72) 
Presenting complaint*  
Abnormal uterine bleeding 55 (90.16) 
Pain 16 (26.23) 
Loss of weight 13 (21.31) 
Abnormal discharge 9 (14.75) 
Other 9 (14.75) 
Comorbid diseases*  
Hypertension 52 (85.25) 
Diabetes 20 (32.79) 
Osteoarthritis 7 (11.48) 
Ischemic heart disease 6 (9.83) 
Hypercholesterolemia 6 (9.83) 
History of breast cancer 4 (6.56) 
Other 11 (18.03) 
Family history of cancer#  
Yes 11 (18.03) 
No 49 (80.33) 
Unknown 1 (1.64) 
Pap smear results  
Result not available 17 (27.87) 
Unsuitable for interpretation 2 (3.28) 
Normal 13 (21.31) 
Abnormal 29 (47.55) 
Pre-operative biopsy results  
Suggestive of carcinosarcoma 32 (52.46) 
Suggestive of other malignancy or poorly differentiated tumour 22 (36.07) 
Not done/unsuitable for diagnosis 7 (11.48) 
HIV status  
Negative 55 (90.16) 
Positive$ 1 (1.53) 
Unknown 5 (8.20) 
RPR status  
Negative 52 (85.25) 
Positive 1 (1.64) 
Unknown 8 (13.11) 
Figo Stage presentation  
Figo I 18 (29.51) 
Figo II 5 (8.20) 
Figo III 16 (26.23) 
Figo IV 22 (36.07) 
Five-year progression-free survival 17.3% (CI 8.9%-27.9%) 
Overall 5-year survival 19.7% (CI 10.6%-30.8%) 
*Some patients presented with a combination of factors 
#First degree relative only of any cancer 
$CD4 count 458 
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Figure 5-1: Kaplan-Meier curve depicting 5-year overall survival. 
 
 
 
Figure 5-2: Kaplan-Meier curve depicting 5-year progression-free survival. 
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5.2 Surgical-pathological characteristics of the study cohort 
The surgical management and debulking status of patients are summarized in Table 5-2 and 
histopathological data is given in Table 5-3.  Eleven of the 61 patients did not undergo surgery.  
This was due to advanced disease at presentation (5 patients), not being surgical candidates 
due to medical conditions (4 patients), and 2 patients declining surgery.  Only 11 patients 
received a TAH/BSO/Omentectomy/PLND.  Complete debulking (no macroscopic tumour) was 
obtained in 28 patients and 14 patients had incomplete debulking (any macroscopic tumour 
left).  In patients that received a pelvic lymphadenectomy, the mean lymph node yield per 
patient was 19 nodes.   
 
Table 5-2: Surgical management and debulking status of patients 
 
&Includes one patient that had additional sigmoidectomy with a Hartmann’s pouch and 
 colostomy as part of debulking 
$Includes one patient that had a rectosigmoidectomy with a Hartmann’s pouch and colostomy 
*Includes one patient that had a vaginal hysterectomy and BSO 
 
 
 
 
 
 
 
 
 
 
 
 
  
Surgical procedures performed No. (%) (n=61) 
TAH/BSO/Omentectomy/PLND& 11(18) 
TAH/BSO/PLND/evaluation of omentum 4(6.6) 
TAH/BSO/Omentectomy$ 8(13.1) 
TAH/BSO* 18(29.5) 
TAH 2(3.3) 
Subtotal hysterectomy/BSO/Omentectomy 1(1.6) 
Subtotal hysterectomy/Omental biopsy 1(1.6) 
Surgery aborted(open/close) 5(8.2) 
No surgery 11(18) 
Debulking status (n=50) 
Complete debulking 28(56) 
Incomplete debulking 14(28) 
Unknown 8(16) 
Lymph nodes (n=15) 
Total amount of lymph nodes removed 284 
Mean (range) 19(1-43) 
Number of node-positive patients 4(26.7) 
Number of positive nodes 7(2.5) 
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Table 5-3: Histopathological tumour data 
Histopathological tumour data No (%) (n=61) 
Tumour diameter (mm)*  
Mean(range) 90.22(10-300) 
Histopathological type#  
Homologous 11(18.03) 
Heterologous 40(65.57) 
Unknown/not reported 10(16.40) 
LVSI#  
Yes 15(24.60) 
No 23(37.70) 
Unknown 23(37.70) 
Myometrial invasion  
<1/2 21(34.42) 
>1/2 29(47.54) 
Unknown 11(18.03) 
Lower segment involvement  
Yes 26(42.62) 
No 16(26.22) 
Unknown 19(31.14) 
Cervical involvement#  
Yes 23(37.70) 
No 24(39.34) 
Unknown 14(22.95) 
Adnexal spread  
Yes 14(22.95) 
No 33((54.10) 
Unknown 14(22.95) 
Necrosis#  
Yes 41(67.21) 
No 7(11.47) 
Unknown 13(20.00) 
*Determined on surgically resected specimen (information only available in 41 patients) 
#Determined on biopsy or surgically resected specimen 
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5.3 Other employed modalities in the treatment of patients 
Non-surgical, adjuvant and palliative treatment was individualized for each patient after 
multidisciplinary discussion.  Other modalities employed were chemotherapy, radiation therapy 
or hormonal therapy.  Only 33 patients (54%) of the entire cohort received some form of other 
therapy – either as part of curative intent or for palliation purposes.  A summary of the 
modalities is given in Table 5-4. 
Table 5-4: Other modalities employed in the treatment of patients 
Modality employed Number (%) (n=61) 
WPI plus brachytherapy 7(11.5) 
WPI  3(4.9) 
Brachytherapy 5(8.2) 
Chemotherapy and vault brachytherapy 2(3.3) 
Chemotherapy and WPI 1(1.6) 
Chemotherapy 5(8.2) 
Palliative radiotherapy* 9(14.8) 
Palliative hormonal therapy 1(1.6) 
No other modality employed 28(45.9) 
*Including high-dose palliation WPI or single fraction radiotherapy 
 
 
5.4 Recurrence of disease 
Seventeen patients presented with documented recurrence (diagnosed clinically or 
radiologically).  Of these 17 recurrences, 5 patients (29.41%) were initially early stage (FIGO 
stage I or II).  The sites of recurrences are tabulated in Table 5-5.  Five patients (29.41%) 
presented with local recurrence only and 12 patients (70.59%) presented with recurrence 
outside the pelvis with or without local recurrence).  Of the 5 patients that presented with local 
recurrence, none had adjuvant therapy after initial management.  Of the 12 patients that 
presented with recurrence outside the pelvis, only 7 patients (58%) received adjuvant 
treatment and chemotherapy was included in only 4 of the regimens. 
 
Table 5-5: Sites of recurrences 
Site of Recurrence Number (%) n=17 
Pelvis (local) 5(29.41) 
Abdominal 1(5.89) 
Distant 3(17.65) 
Pelvic and abdominal 2(11.76) 
Abdominal and distant 5(29.41) 
Pelvis, abdominal and distant 1(5.89) 
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5.5 Identification of prognostic factors associated with progression and overall 
survival 
The results of univariate and multivariate analysis are summarized in Table 5-6 and Table 5-7.  
In univariate analysis of PFS, only tumours with a diameter equal or more than 100mm (HR 
4.57, p-value 0.005) was a significant factor for progression, but data were only available for 
41 patients.  In univariate analysis of OS, several variables were statistically significant.  A 
positive family history (HR 0.42, p-value 0.047), receiving a full staging operation (HR 0.37, p-
value 0.008) and receiving any other modality of treatment (HR 0.48, p-value 0.012) were 
associated with better survival, while an abnormal pap smear (HR 2.4, p-value 0.041), late-
stage disease (HR 3.48, p-value <0.001), presence of residual tumour (HR 3.66, p-value < 
0.001), myometrial invasion more than 50% (HR 2.29, p-value 0.019), cervical involvement 
(HR 3.38, p-value 0.001) and adnexal involvement (HR 3.21, p-value 0.002) were associated 
with higher risk of death. 
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Table 5-6: Univariate analysis of PFS and OS in patients with uterine carcinosarcoma 
(significant p-values in bold) 
Variable Progression-free survival Overall survival 
 Hazard 
ratio 
95%CI p-value Hazard 
ratio 
95% CI p-value 
Age  
(> 60yr vs <60yr) 
 
1.20 
 
0.35-4.13 
 
0.771 
 
1.1 
 
0.53-2.28 
 
0.794 
Family history 
(yes vs no) 
 
1.00 
 
0.29-3.51 
 
0.999 
 
0.42 
 
0.18-0.99 
 
0.047 
Pap Smear 
(abnormal vs normal) 
 
1.45 
 
0.43-4.89 
 
0.548 
 
2.40 
 
1.03-5.60 
 
0.041 
Stage 
(late vs early)* 
 
1.54 
 
0.56-4.25 
 
0.400 
 
3.48 
 
1.79-6.77 
 
0.000 
Residual tumour 
(yes vs no) 
 
0.41 
 
0.13-1.32 
 
0.135 
 
3.66 
 
1.90-7.02 
 
0.000 
Histology (homologous vs 
heterologous) 
 
0.44 
 
0.10-1.88 
 
0.270 
 
0.71 
 
0.31-1.62 
 
0.418 
LVSI 
(positive vs negative) 
 
0.78 
 
0.27-2.22 
 
0.639 
 
1.38 
 
0.77-3.47 
 
0.200 
Myometrial invasion > 50% 
(yes vs no) 
 
0.67 
 
0.26-1.72 
 
0.403 
 
2.29 
 
1.15-4.57 
 
0.019 
Lower segment 
involvement (yes vs no) 
 
1.39 
 
0.50-3.89 
 
0.529 
 
1.86 
 
0.89-3.90 
 
0.098 
Cervical involvement 
(yes vs no) 
 
1.61 
 
0.63-4.13 
 
0.325 
 
3.38 
 
1.64-6.97 
 
0.001 
Adnexal involvement 
(yes vs no) 
 
0.663 
 
0.21-2.05 
 
0.475 
 
3.21 
 
1.56-6.63 
 
0.002 
Necrosis 
(yes vs no) 
 
2.45 
 
0.34-17.60 
 
0.372 
 
1.97 
 
0.70-5.58 
 
0.200 
Tumour diameter 
=>100mm 
(yes vs no) 
 
4.57 
 
1.59-13.19 
 
0.005 
 
1.75 
 
0.75-4.07 
 
0.192 
Full staging 
(yes vs no) 
 
2.42 
 
0.94-6.27 
 
0.069 
 
0.37 
 
0.18-0.78 
 
0.008 
Any other modality 
treatment# (yes vs no) 
 
0.70 
 
0.27-1.80 
 
0.455 
 
0.48 
 
0.27-0.85 
 
0.012 
*Early-stage regarded as FIGO stage I and II and late-stage as Figo stage III and IV 
#Including chemotherapy, radiation or hormonal therapy – as part of curative or for palliation intent 
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Due to the limited sample size and some missing data, all the variables could not be tested in 
the multiple regression models.  In the multivariate analysis, only full staging surgery was 
statistically significant associated with a risk of progression of disease (HR 3.49, p-value 
0.025).  Advanced stage (HR 4.2, p-value < 0.001) was statistically significant associated with 
a higher risk of death.  Any other modality of treatment (HR 0.28, p-value < 0.001) and full 
staging surgery (HR 0.27, p-value 0.001) was a protective factor for death.  Kaplan-Meier 
survival estimates according to the stage of disease, receiving any other modality of treatment 
and receiving a full staging procedure is shown in Figure 5-3 to 5-5. 
As tumour diameter (≥100mm) was a significant factor associated with progression in the 
univariate analysis, the same regression model was used by including this variable as well 
(data not shown).  However, as tumour diameter data was only available for 41 patients, 
multiple regression could only be applied to 41 patients.  Tumour diameter ≥ 100mm was a 
risk factor for progression (HR 10.35, p-value 0.011, CI 1.72-62.1), but the confidence intervals 
were extremely wide due to the small number of events and adjustments.  It was not a 
significant factor in OS (HR 2.09, p-value 0.110, CI 0.85-5.17).  Imputation analysis to account 
for the missing tumour diameter indicators data, using a logistic regression imputation model 
with covariates of age and stage, was also attempted.  Tumour diameter ≥100mm was no 
longer a significant factor in progression of disease (HR 4.64, p-value 0.086, CI 0.80-26.94) or 
overall survival (HR 1.66, p-value 0.221, CI 0.73-3.78).  The true association of tumour 
diameter on progression is therefore uncertain.   
 
Table 5-7: Multivariate analysis of factors influencing PFS and OS (significant p-values in 
bold) 
Variable Progression-free survival Overall survival 
 Hazard 
ratio 
95%CI p-value Hazard 
ratio 
95% CI p-value 
Age 1.34 0.36-4.96 0.657 0.79 0.38-1.65 0.526 
Stage (late vs early) 2.39 0.69-8.31 0.172 4.20 2.09-8.44 0.000 
Any other modality 
treatment (yes vs no) 
0.67 0.27-1.70 0.401 0.28 0.15-0.53 0.000 
Full staging (yes vs 
no) 
3.49 1.17-10.41 0.025 0.27 0.12-0.59 0.001 
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Figure 5-3: Overall survival according to the stage of disease. 
 
Figure 5-4: Overall survival according to receiving any other modality of treatment 
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Figure 5-5: Overall survival according to receiving a full staging procedure 
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6 Discussion 
In this study, a descriptive account of patients treated for uterine carcinosarcoma in our unit 
over a period of 10 years, was presented.  Clinical characteristics, surgical-pathological 
factors, treatment, follow-up and survival data were presented.  Important prognostic factors 
associated with PFS and OS were identified. 
The 5-year overall survival of 19.7% is much worse than what is described in the international 
literature, with 5-year survival ranging from 33 to 39%7,8.  Reasons for this is unclear, but 
differences in tumour biology or patient genetics in our population might be at play.  Also, 
62.3% of patients presented with advanced disease (FIGO III and IV).  Poor access to services 
may be the cause of the late presentation.  A 2-year progression-free survival appears to be 
more realistic given the high mortality of patients, as this was the same as the 5-year 
progression-free survival of 17.3%. 
Important risk factors that have been associated with uterine carcinosarcoma (obesity, 
nulliparity, exogenous estrogen use, the protective effect of oral contraceptives, association 
with tamoxifen therapy and previous radiotherapy)19–24 were present in our population.  The 
mean BMI of the cohort was 32.86 and 2 patients had a history of tamoxifen use.  However, 
nulliparity (median parity was 4) and a history of previous pelvic radiotherapy were not present.  
There was a high incidence and spectrum of comorbid diseases related to obesity in the study 
population (hypertension, diabetes, ischemic heart disease and hypercholesterolemia). 
The poor performance of pap smear as a screening test in detecting uterine malignancy is well 
known and it is not used for this indication.  The sensitivity of 65.91% of a pap smear in 
detecting uterine malignancy was surprisingly high.  But all patients were symptomatic, and 
this was not used as screening. 
Of the entire cohort, 82% of the patients received surgery and only 54% of the patients received 
some sort of other therapy, either as part of curative treatment or as part of symptom palliation.  
It is well established that surgery is the cornerstone of treatment of any uterine cancer and 
complete debulking should be the primary goal.  The heterogeneity in which and how patients 
received other types of therapy demonstrate the lack of evidence supporting adjunctive 
treatment and highlights the need for universal, evidence-based protocols. Although several 
retrospective series and prospective non-randomized trials on treatment and outcome have 
been published50,51,55–64,66,67, only 3 prospective randomized trials are available to guide 
treatment and a fourth is ongoing.  The first is a Gynecologic Oncology Group randomized 
phase III trial of whole abdominal irradiation (WAI) versus cisplatin-ifosfamide and mesna 
(CIM) as post-surgical therapy in stage I-IV uterine carcinosarcoma52.  The trial did not find a 
statistically significant advantage in recurrence rate or survival of adjuvant CIM over WAI.  
Another GOG randomized phase III trial in advanced uterine carcinosarcoma demonstrated a 
superior OS for combination chemotherapy (ifosfamide with paclitaxel) compared with single-
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agent treatment (ifosfamide alone)53.  A Phase 3 randomized study conducted by the European 
Organisation for Research and Treatment of Cancer evaluated the role of adjuvant pelvic 
radiotherapy for early-stage uterine sarcomas (including 91 patients with UCS)68.  The study 
confirmed a trend towards better local control (but also higher distant metastatic rate) and no 
significant impact on either PFS or OS.  GOG 261, the latest randomized phase III trial 
comparing the combination of carboplatin and paclitaxel versus the combination of ifosfamide 
and paclitaxel for UCS, is ongoing (NCT00954174). 
The recurrence rate of 27.9% in our series is lower than that reported in other studies.  Yamada 
et al.37 reported a recurrence rate of 55% and the majority of these (42%) had an extra-pelvic 
component.  More recent studies also reported higher recurrence rates (44.7%) with 55% of 
recurrences being extra-pelvic38.  Our recurrence rate most likely represents an underestimate 
of the true recurrence rate as the overall survival was poor.  As death is a competing risk for 
progression, this was considered and incorporated in the survival analysis.  A large percentage 
of patients most likely died from aggressive disease before a recurrence could be identified.  
However, in the recurrence group, 70.6% of patients presented with recurrence not confined 
to the pelvis.  Of this group, only 33.3% had initial chemotherapy as adjuvant treatment.  It 
appears that we are not using enough chemotherapy in our setting.  Of the 5 patients (29.4%) 
that presented with local recurrence, none had adjuvant treatment.  As adjuvant treatment was 
individualized based on several factors and not standardized, it is difficult to make conclusions 
about optimal adjuvant treatment.  However, the failure pattern of carcinosarcoma (in our study 
and others above), appear to favour a high rate of local and/or distal relapse.  Many 
retrospective case series and prospective non-randomized published reports69–79 suggested a 
longer survival with a combination of radiation and chemotherapy regimens.  The schedule 
and sequence remain controversial across these studies and no quality of life studies are 
available on the toxicity profile combining these two radical treatment modalities. 
. 
In the univariate analysis of PFS, only tumour diameter ≥ than 100mm was significant for 
progression.  In the multivariate analysis of PFS, this association was questionable (see results 
section).  Full staging surgery was also associated with risk of progression of disease. 
In the univariate analysis of OS, several variables were statistically significant.  A positive 
family history, receiving a full staging operation, and receiving any other modality of treatment 
was associated with better survival.  An abnormal pap smear, late stage disease, presence of 
residual tumour, myometrial invasion of more than 50%, cervical involvement and adnexal 
involvement was associated with higher risk of death.  In multivariate analysis, advanced stage 
was associated with poorer overall survival.  Receiving a full staging laparotomy and receiving 
any other modality of treatment (with or without surgery) significantly reduced the risk of death. 
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Several studies9,37–43,49,67 have reported on pathological and clinical factors predictive of 
recurrence and survival.  Among these, age, stage, Ca125 level, myometrial invasion, LVSI, 
positive cytology, adnexal involvement, serosal involvement, lymph node involvement, number 
of lymph nodes harvested, tumour size, adjuvant radiotherapy, poor performance status, 
postsurgical residual tumour size greater than 1cm, histologic cell type (heterologous versus 
homologous), were all shown to carry prognostic significance. 
The impact of advanced stage on recurrence-free and overall survival is well known, but we 
could not confirm the prognostic significance of older age with poorer disease-free and overall 
survival. 
The data confirmed that a full staging laparotomy (including pelvic lymphadenectomy) has a 
significant effect on overall survival.  Although the significance of the number of lymph nodes 
harvested could not be tested due to limited patient cohort, the mean lymph node yield per 
patient was high (19).  Some studies have confirmed that lymphadenectomy offers a 
measurable survival benefit beyond staging information7.  This may be related to the 
therapeutic benefit that has been alluded to in the benefit of lymphadenectomy in other high-
risk endometrial cancers as well83.  In a matched cohort analyses in stage 1 UCS (5 614 women 
identified from the National Cancer Database)78, it was concluded that the removal of at least 
15–20 lymph nodes are associated with increased survival.  One of the largest multi-
institutional retrospective studies to date from the Japanese Gynecologic Oncology Group41, 
examined prognostic factors in 486 patients with stage I-IV uterine carcinosarcoma and 
concluded pelvic lymphadenectomy was associated with improved DFS and OS and may be 
necessary for the surgical management of UCS.  Para-aortic lymphadenectomy did not 
influence these parameters.  A large SEER-based analysis67 (including 1 855 patients with 
Stage I-III uterine carcinosarcoma) showed that disease-free survival and five-year overall 
survival (49% vs 34%) were significantly improved for patients receiving lymph node dissection 
compared to patients that received no lymph node dissection.  This is an important finding for 
several reasons.  Controversy exists regarding the necessity and type of lymphadenectomy 
that should be performed in patients with uterine carcinosarcoma.  In our own dataset, lymph 
node metastases were present in 26.67% of patients that did undergo a pelvic 
lymphadenectomy.  Also, in an old GOG9 study of 301 patients with uterine carcinosarcoma, 
20 % of patients with early-stage disease already had lymph node metastasis.  In our cohort, 
full staging was done equally across stages (53.33% in stage I-II UCS and 46.67% in patients 
with stage III-IV UCS), minimizing the risk of selection bias with this result.  
The finding of full staging surgery relating to a significant risk of progression of disease seems 
contradictory.  Because full staging surgery was associated with such a significant survival 
benefit, more patients were alive in this group to experience the event of progression.  This 
also highlights the importance of accurate pre-operative histology to guide appropriate surgery. 
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Full staging laparotomy, including pelvic adenectomy, is therefore necessary for accurate 
staging and improved survival outcomes.  Patients with uterine carcinosarcoma should be 
managed in tertiary centers with the necessary surgical expertise.  The guidelines offered by 
the NCCN are also in support of this surgical approach in uterine carcinosarcoma45. 
The finding that patients who receive any other modality type of treatment (for curative or 
palliation intent, with or without surgery) have better overall survival, highlights the important 
principle that uterine carcinosarcoma is responsive (at least partially) to chemotherapy and 
radiation therapy.  However, we need to be careful to draw conclusions from our small sample 
size.  Perhaps better prognosis patients received treatment.  Other modality therapy should be 
considered and offered to patients, even if the situation seems futile due to advanced or 
unresectable disease.   
Our study had several limitations.  It was a retrospective study, which may be prone to biases.  
Surgical and adjuvant treatments were not standardized.   It consisted of a small sample size 
with incomplete data sets.  This limited our statistical analysis in evaluating prognostic data 
and may have increased selection bias.  
Strengths included that we had 5-year outcome data available on the entire cohort.  All the 
histological data were reviewed by an expert in gynaecological malignancies.  To our 
knowledge, this is the first series review of this type of tumour on the African continent. 
In conclusion, uterine carcinosarcoma carries much worse survival in our population than what 
is quoted in the international literature.  Standard protocols need to be developed in managing 
these cancers.  They need to be managed in tertiary, high-volume centers with expertise in 
gynecological oncology surgery.  Full staging surgery (including TAH, BSO, pelvic 
lymphadenectomy and omental evaluation) carries a significant survival benefit.  Patterns of 
recurrence and the survival benefit of modalities other than surgery alone, suggest the need 
for adjuvant local control modalities and systemic treatment to decrease recurrence and 
improve survival.  After interpreting the data, it is clear that the management of these patients 
need to be better in terms of surgical intervention and the incorporation of more aggressive 
adjunctive treatment modalities. 
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